PLAUR and pachyonychia congenita: In fact, we have conducted two preclinical proof-of-concept studies with DOTA-AE105 conjugated with the beta-emitter 177Lu for uPAR-targeted radionuclide therapy in colorectal cancer [51] and in metastatic PC [48].